Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Drug:
gp100 antigen
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of High-Dose Aldesleukin With or Without gp100 Antigen in Patients With Locally Advanced or Metastatic Cutaneous Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CCCGHS-NCI-T98-0085
, NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682
2.
Phase II Study of Adoptive Transfer of Cloned Lymphocytes With Interleukin-2 After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0158
, NCI-T99-0078, T99-0078, NCT00019942
3.
Phase II Randomized Study of Immunization With Autologous Dendritic Cells (DC) Pulsed With gp100 Antigen Versus Autologous DC Fused With Autologous Tumor Cells in Patients With Stage III or IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
DFCI-03123
, NCT00085397
4.
Melanoma Vaccine With Peptides and Leuprolide
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2004-0502
, NCT00254397
5.
Phase II Randomized Study of Adjuvant gp100 Peptide Immunization With or Without Montanide ISA 51 and/or Imiquimod in Patients With Resected High-Risk Melanoma (Treatment Arms I-IV Closed to Accrual as of 1/11/08)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0069
, 7676, NCI-7676, NCI-P6703, NCT00304057
6.
Phase I Randomized Pilot Study of Fludarabine Followed By Vaccination Comprising Modified gp100 Peptide, Montanide ISA-51, and Keyhole Limpet Hemocyanin Combined With Autologous Peripheral Blood Mononuclear Cell Reinfusion in Patients With Unresectable or Metastatic Melanoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
PPMC-IRB-02-99
, NCI-6361, 6361, NCT00091143
7.
Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
Pro00000806
, IND # BB-13545, NIH OBA # 0708-874, NCT00672542
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute